Core Insights - Humana's leadership expressed confidence in membership growth and emphasized a strategy focused on maximizing customer lifetime value through sustainable pricing and strong retention rather than loss leader plans [1] - The company reported adjusted EPS of $17.14 for 2025, exceeding initial guidance of approximately $16.25, and indicated that higher-than-planned investments were made to accelerate transformation [3][6] - Humana anticipates a significant earnings headwind related to Stars, estimated at approximately $3.5 billion for 2026, guiding to at least $9 adjusted EPS for that year [5][10] Membership Growth and Retention - Humana added approximately 1 million Medicare Advantage members, representing a 20% increase during the Annual Enrollment Period (AEP), with retention improving by over 500 basis points year over year [5][7] - The company expects individual Medicare Advantage membership growth of around 25% in 2026, supported by a favorable sales mix with over 70% of new sales coming from switches from competitor plans [5][9] Financial Performance and Guidance - The full-year insurance segment benefit ratio was reported at 90.4%, slightly better than guidance, which included a benefit set aside for a potential "Doc Fix" in 2025 [2] - Humana's initial guidance for 2026 reflects a conservative approach due to a dynamic environment, with expectations of a doubling of individual Medicare Advantage pre-tax margins when normalizing for Stars [10] Operational Efficiency and Cost Management - Management expects significant improvement in consolidated operating costs ratio in 2026, driven by operating leverage from membership growth and tactical cost-cutting efforts [13] - The company is focused on capital efficiency through optimizing legal structures and managing capital deployment, expecting debt-to-capital levels to remain largely flat year over year [14] Strategic Initiatives and Leadership Changes - Humana is expanding its Medicaid services across 13 states and anticipates announcing a strategic acquisition in the primary care space [15] - Aaron Martin joined Humana as President of Medicare Advantage, expected to elevate to the president of insurance role upon the retirement of the current president [18]

Financial Data and Key Metrics Changes - The company reported adjusted EPS of $17.14 for 2025, exceeding initial guidance of approximately $16.25 [17] - The full-year insurance segment benefit ratio was 90.4%, slightly better than guidance [18] - For 2026, the company expects full-year adjusted EPS of at least $9, with a year-over-year decline anticipated due to a $3.5 billion headwind from Stars [19][21] Business Line Data and Key Metrics Changes - The company grew by approximately 1 million members, or 20%, during the Annual Enrollment Period (AEP) [8] - Retention rate improved by over 500 basis points year-over-year, with over 70% of new sales coming from switches from competitor plans [9] - The company expects individual Medicare Advantage (MA) membership growth of approximately 25% for full year 2026 [10] Market Data and Key Metrics Changes - The company absorbed approximately 12% of members impacted by competitor plan exits, which is less than its market share [9] - Nearly 30% of new sales were bounce-back members, indicating a positive mix of new sales [9] Company Strategy and Development Direction - The company remains committed to a consumer-centric strategy and aims to unlock earnings potential by 2028 [5][6] - Focus areas include product and experience, clinical excellence, operational efficiency, and capital allocation [6] - The company is expanding its Medicaid and CenterWell footprint, with Medicaid now spanning 13 states [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational capacity to absorb growth and emphasized the importance of maintaining quality care for members [10] - The company is aware of the fiscal pressures on Medicare Advantage and is prepared to adapt to the funding environment [15] - Management remains optimistic about achieving top quartile Stars results by 2028 [12] Other Important Information - The company plans to announce a strategic acquisition in the primary care space [14] - Aaron Martin joined the company as President of Medicare Advantage, bringing extensive healthcare experience [16] Q&A Session Summary Question: Can you expand on the level of earnings outside of MA underwriting? - Management indicated that earnings associated with CenterWell will contribute positively, with significant tailwinds expected from new membership [30] Question: How do you estimate the progress of new members' margins over time? - Management expects substantial margin improvement in the first year due to reduced marketing load and improved medical benefit ratios [35] Question: What are the expectations for D-SNP membership growth? - The absolute number of new D-SNP members exceeded expectations, although the percentage growth was slightly lower [48] Question: How did expectations for 2026 change since Investor Day? - The primary difference is the embedded conservatism in the guidance, reflecting known headwinds and tailwinds [45] Question: What is the impact of the Stars headwind on margins? - The Stars headwind for 2026 is approximately $3.5 billion, affecting both individual and group MA margins [21] Question: How will the company adjust to the rate notice? - Management stated they will adapt to the final rate notice and advocate for appropriate funding levels [59]

Group 1 - Evercore ISI initiated coverage on Humana (NYSE: HUM) with an In Line rating and a $295 price target, indicating that the company's long-term growth potential is offset by near-term uncertainty [1] - Humana has a market cap of approximately $33 billion and is positioned to grow adjusted EBIT at a low double-digit rate and EPS at a mid-teens CAGR post-2028 [1] - The medium-term outlook for Humana is less clear as the company works toward normalized margins [1] Group 2 - Management's goal to achieve top-quartile Stars performance by 2028 is considered achievable, although no Stars benefit is modeled for 2027 [2] - Risks from competitive Medicare Advantage pricing could lead to higher-than-expected utilization in 2026 [2] - Current valuation reflects a fair balance of risks and opportunities, with upside potential dependent on clarity around Stars, operating leverage, and the 2026 enrollment period [2]